Results 121 to 130 of about 12,634 (264)
How Can Multi-Criteria Portfolio Decision Analysis Help Mitigate Mis/Disinformation? [PDF]
Salo A, Olander L, Raivio T.
europepmc +1 more source
Association Between Neurofilament Light Chain and Real‐World Ambulatory Function in Progressive MS
ABSTRACT Objective Neurofilament light chain (NfL) is a biomarker of neuroaxonal injury in multiple sclerosis (MS), yet associations with functional outcomes remain unclear. Longitudinal associations between serum NfL (sNfL) and daily step count (STEPS) from wearable devices were assessed in a large international progressive MS cohort.
Gabby B. Joseph +5 more
wiley +1 more source
Voters reveal public library value: Evidence from US referendums. [PDF]
Gustina M, Berrens RP.
europepmc +1 more source
ABSTRACT Background The clinical relevance of MGMT promoter methylation in IDH‐mutant gliomas remains controversial in the era of molecular classification. We aimed to systematically evaluate its clinical relevance by integrating quantitative assessment, cutoff exploration, and adjustment for clinical confounding.
Haihui Jiang +7 more
wiley +1 more source
Can a public information campaign increase trust in American elections? [PDF]
Kousser T +3 more
europepmc +1 more source
Anticoagulation Treatment Response Among Phenotypic ESUS Clusters: Evidence From CASPR
ABSTRACT Objective To evaluate treatment effect heterogeneity across phenotypic clusters of patients with cryptogenic embolic stroke using causal inference methods. Methods From a retrospective, multicenter cohort of patients with cryptogenic embolic stroke, we estimated the treatment effect of anticoagulation versus antiplatelet therapy in patients ...
Elena Badillo Goicoechea +53 more
wiley +1 more source
ElecMeter: An index for evaluating dissatisfaction of social decision-making. [PDF]
Shahdoust M +3 more
europepmc +1 more source
Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley +1 more source
Grey voters and populist voting. The role of religiosity and national collective narcissism. [PDF]
Turska-Kawa A, Pilch I.
europepmc +1 more source

